ACADIA PHARMACEUTICALS INC (ACAD) Stock News

NASDAQ:ACAD, an undervalued stock with good fundamentals.

ACADIA PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:ACAD showcases decent financial health and profitability, coupled with an attractive price.

While growth is established for NASDAQ:ACAD, the stock's valuation remains reasonable.

ACADIA PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:ACAD is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.

Mentions: NGNE ACHC TSHA

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What's Going On With ACADIA Pharmaceuticals Stock?

ACADIA Pharmaceuticals shares are trading lower by 4.6% during Tuesday's session. The company appointed Catherine Owen Adams as CEO.

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Ryan Reynolds Announces More to Parkinson’s® Campaign

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.

Mentions: MDGL ITCI

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024